SLU-PP-332 — Safety, Research, Risks & Legal Status

Not medical advice. SLU-PP-332 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	SLU PP 332, SLUPP332, pan-ERR agonist (research tool compound)
Category	Research Chemical
Drug class	Synthetic small-molecule pan-agonist of estrogen-related receptors (ERRalpha/beta/gamma)
Primary target	ERRalpha (highest potency), with weaker activity at ERRbeta and ERRgamma
Developer	Thomas Burris lab (Saint Louis University, later University of Florida) and collaborators
Trial stage	Preclinical only (cell and rodent studies); no human trials
Route in studies	Injection (intraperitoneal/subcutaneous); poor oral bioavailability
Regulatory status	Not FDA-approved; sold only as research-use-only, not for human consumption
US legal status	Not FDA-approved for any use and not a lawful dietary supplement. SLU-PP-332 is an investigational small molecule that exists only as a preclinical research tool compound; as of this writing it has not entered human clinical trials. It does not meet the FDA definition of a dietary ingredient and cannot be lawfully sold or marketed for human consumption in the United States. Where it is offered online it is sold strictly as a "research chemical, not for human consumption," typically labeled research-use-only (RUO). Using vendor-sold material outside a bona fide research setting carries regulatory and safety risk, and such material is unregulated as to identity, purity, and dose.

What is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule agonist of the estrogen-related receptors (ERRalpha, ERRbeta, ERRgamma), a family of orphan nuclear receptors that act as master transcriptional regulators of mitochondrial energy metabolism. It was designed as a pharmacological "exercise mimetic": by directly activating the ERR transcriptional program, it aims to reproduce some of the muscle and metabolic gene-expression changes normally driven by acute aerobic exercise, without the physical activity itself. It is an early-stage research tool compound, not an approved drug. All published efficacy data come from cell-based assays and rodent studies, and there are no human trials.

How it works

SLU-PP-332 binds and activates the estrogen-related receptors, orphan nuclear receptors with no known endogenous hormone ligand. It is described as a pan-ERR agonist with greatest potency at ERRalpha (reported cell-based EC50 values on the order of ~0.1 to ~0.2 micromolar for ERRalpha, with several-fold weaker activity at ERRbeta and ERRgamma; exact values vary by assay). ERRalpha, working with the coactivator PGC-1alpha, is a central node in the transcriptional network that governs mitochondrial biogenesis, oxidative phosphorylation, and fatty-acid oxidation, and its activity normally rises with exercise. By stabilizing the active ERR conformation, SLU-PP-332 drives this gene program in skeletal muscle and other metabolic tissues, producing an "exercise-like" metabolic state without the mechanical stimulus. This is a proposed and preclinically supported mechanism; it has not been validated in humans.

Background & history

SLU-PP-332 was developed as a research tool by Thomas Burris and colleagues, whose ERR program originated at Saint Louis University (the source of the "SLU" designation) and continued at the University of Florida. It grew out of longstanding interest in nuclear-receptor pharmacology and the search for small molecules that could pharmacologically mimic exercise for metabolic disease. The compound gained broad public attention in 2023 through university press releases and science media coverage describing weight loss and endurance gains in mice. Since then, the group and collaborators have pursued structural optimization to overcome SLU-PP-332's pharmacokinetic limitations (poor solubility, high lipophilicity, and limited oral exposure), producing follow-on analogs such as SLU-PP-915 aimed at oral activity and improved metabolic stability.

What the research says

The core preclinical work comes from the laboratory of Thomas Burris (Saint Louis University, later University of Florida) and collaborators; the "SLU" prefix reflects the Saint Louis University origin. In a widely reported 2023 mouse study, twice-daily dosing raised whole-body energy expenditure (reported around 25 percent) and shifted fuel use toward fatty-acid oxidation, reflected in a lower respiratory exchange ratio. Treated normal-weight mice were reported to run substantially longer and farther in endurance tests, and obese mice reportedly lost around 12 percent of body weight and gained far less fat than untreated controls despite eating the same amount of food and not exercising more. The mechanism is ERRalpha-dependent and recapitulates an acute-exercise gene program. Important caveats: efficacy studies used injection (intraperitoneal/subcutaneous) rather than oral dosing, the treatment windows were short (roughly a month), and there is no published long-term safety, carcinogenicity, or reproductive data. Human pharmacokinetics and efficacy remain entirely unstudied. Subsequent medicinal-chemistry work has focused on making orally active, more metabolically stable analogs (for example SLU-PP-915 and related compounds), which underscores that SLU-PP-332 itself is a lead/tool compound rather than a finished clinical candidate.

Reported effects

Reported in rodent studies only, not demonstrated in humans
Increased whole-body energy expenditure and metabolic rate in mice (reported ~25%)
Shift toward fatty-acid oxidation as fuel (lower respiratory exchange ratio) in mice
Improved running endurance and distance in mice without added training
Fat loss and reduced fat accumulation in obese mice without reduced food intake
Upregulation of mitochondrial-biogenesis and oxidative-metabolism genes (an exercise-like transcriptional signature)
No appetite suppression observed (food intake unchanged in animal studies)

Dosing & administration (informational)

Informational only, not a protocol and not dosing guidance. There is no established or approved human dose for SLU-PP-332, and no human pharmacokinetic data have been published. In published animal work, efficacy doses were given by injection (intraperitoneal or subcutaneous), typically on a twice-daily schedule over a period of weeks, and the compound has poor oral bioavailability that motivated development of newer analogs. The milligram-per-kilogram amounts used in mice cannot be scaled to a safe or meaningful human dose. Any figures circulating on vendor sites are not derived from human studies and should not be treated as a protocol.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

No human safety data exist; the full human side-effect, toxicity, and interaction profile is unknown
Preclinical reports noted no severe acute toxicity at tested doses, but studies were short (roughly one month) with no long-term or chronic-exposure data
ERRs regulate metabolism in heart, liver, and muscle, so broad ERR activation could have off-target cardiac or hepatic effects that have not been characterized in humans
No carcinogenicity, genotoxicity, or reproductive/developmental toxicity studies have been published
Vendor-sold RUO material is unregulated: actual identity, purity, dose accuracy, and contaminants are unverified and can vary widely
Injectable use of non-sterile research-grade material introduces infection and contamination risk independent of the compound itself
No established human dose, meaning any human use is uncontrolled self-experimentation

Drug & supplement interactions

N
o
h
u
m
a
n
d
r
u
g
-
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
e
x
i
s
t
,
s
o
a
n
y
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
i
s
t
h
e
o
r
e
t
i
c
a
l
.
B
e
c
a
u
s
e
S
L
U
-
P
P
-
3
3
2
b
r
o
a
d
l
y
a
c
t
i
v
a
t
e
s
E
R
R
-
d
r
i
v
e
n
m
e
t
a
b
o
l
i
c
g
e
n
e
p
r
o
g
r
a
m
s
,
p
l
a
u
s
i
b
l
e
b
u
t
u
n
s
t
u
d
i
e
d
c
o
n
c
e
r
n
s
i
n
c
l
u
d
e
a
d
d
i
t
i
v
e
o
r
u
n
p
r
e
d
i
c
t
a
b
l
e
e
f
f
e
c
t
s
w
h
e
n
c
o
m
b
i
n
e
d
w
i
t
h
o
t
h
e
r
m
e
t
a
b
o
l
i
c
o
r
p
e
r
f
o
r
m
a
n
c
e
a
g
e
n
t
s
(
f
o
r
e
x
a
m
p
l
e
o
t
h
e
r
p
u
r
p
o
r
t
e
d
e
x
e
r
c
i
s
e
m
i
m
e
t
i
c
s
,
t
h
y
r
o
i
d
h
o
r
m
o
n
e
,
s
t
i
m
u
l
a
n
t
s
,
o
r
G
L
P
-
1
a
g
o
n
i
s
t
s
)
a
n
d
w
i
t
h
a
n
y
t
h
i
n
g
t
h
a
t
s
t
r
e
s
s
e
s
t
h
e
h
e
a
r
t
o
r
l
i
v
e
r
,
t
i
s
s
u
e
s
w
h
e
r
e
E
R
R
s
a
r
e
a
c
t
i
v
e
.
M
e
t
a
b
o
l
i
s
m
i
s
e
x
p
e
c
t
e
d
t
o
i
n
v
o
l
v
e
h
e
p
a
t
i
c
p
a
t
h
w
a
y
s
,
s
o
c
o
-
u
s
e
w
i
t
h
d
r
u
g
s
t
h
a
t
i
n
h
i
b
i
t
o
r
i
n
d
u
c
e
t
h
o
s
e
p
a
t
h
w
a
y
s
c
o
u
l
d
i
n
p
r
i
n
c
i
p
l
e
a
l
t
e
r
e
x
p
o
s
u
r
e
.
N
o
n
e
o
f
t
h
i
s
i
s
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
h
u
m
a
n
s
;
t
h
e
s
a
f
e
a
s
s
u
m
p
t
i
o
n
i
s
t
h
a
t
i
n
t
e
r
a
c
t
i
o
n
s
a
r
e
u
n
k
n
o
w
n
.

Who should avoid it

Anyone seeking a proven or approved weight-loss or performance drug (this is neither; it is an unproven research compound)
Anyone who would be relying on unregulated, research-use-only material of unverified identity and purity
People with cardiovascular or liver conditions, given ERR activity in those tissues and the absence of human safety data
Pregnant or breastfeeding individuals, given no reproductive or developmental safety data
Anyone unwilling to accept that all human use is uncontrolled self-experimentation with unknown long-term risk

How it is commonly combined

There is no evidence-based rationale for combining SLU-PP-332 with other compounds in humans, and no human data on any such combination. Stacking claims seen in online communities (pairing it with other "research" metabolic agents, peptides, or fat-loss compounds) are speculative and compound the already unknown risk, since each added unregulated substance multiplies uncertainty about interactions, purity, and cumulative toxicity. This reference does not endorse any stack. For the underlying goals people cite (endurance, fat oxidation, metabolic health), the evidence-based approach remains actual aerobic and resistance exercise plus established, regulated interventions discussed with a clinician.

Legal & regulatory. Not FDA-approved for any use and not a lawful dietary supplement. SLU-PP-332 is an investigational small molecule that exists only as a preclinical research tool compound; as of this writing it has not entered human clinical trials. It does not meet the FDA definition of a dietary ingredient and cannot be lawfully sold or marketed for human consumption in the United States. Where it is offered online it is sold strictly as a "research chemical, not for human consumption," typically labeled research-use-only (RUO). Using vendor-sold material outside a bona fide research setting carries regulatory and safety risk, and such material is unregulated as to identity, purity, and dose.

Quality & harm reduction

B
e
c
a
u
s
e
S
L
U
-
P
P
-
3
3
2
i
s
s
o
l
d
o
n
l
y
a
s
a
r
e
s
e
a
r
c
h
-
u
s
e
-
o
n
l
y
c
h
e
m
i
c
a
l
a
n
d
n
o
t
a
s
a
r
e
g
u
l
a
t
e
d
d
r
u
g
o
r
s
u
p
p
l
e
m
e
n
t
,
t
h
e
r
e
i
s
n
o
p
h
a
r
m
a
c
o
p
e
i
a
l
s
t
a
n
d
a
r
d
,
n
o
F
D
A
o
v
e
r
s
i
g
h
t
o
f
m
a
n
u
f
a
c
t
u
r
i
n
g
,
a
n
d
n
o
g
u
a
r
a
n
t
e
e
o
f
w
h
a
t
i
s
a
c
t
u
a
l
l
y
i
n
a
g
i
v
e
n
v
i
a
l
o
r
c
a
p
s
u
l
e
.
A
n
a
l
y
t
i
c
a
l
c
o
n
c
e
r
n
s
i
n
c
l
u
d
e
i
n
c
o
r
r
e
c
t
i
d
e
n
t
i
t
y
,
l
o
w
o
r
v
a
r
i
a
b
l
e
p
u
r
i
t
y
,
u
n
d
i
s
c
l
o
s
e
d
r
e
l
a
t
e
d
s
y
n
t
h
e
t
i
c
i
m
p
u
r
i
t
i
e
s
,
i
n
c
o
r
r
e
c
t
l
a
b
e
l
e
d
q
u
a
n
t
i
t
y
,
a
n
d
,
f
o
r
r
e
c
o
n
s
t
i
t
u
t
e
d
i
n
j
e
c
t
a
b
l
e
s
,
n
o
n
-
s
t
e
r
i
l
i
t
y
.
I
n
d
e
p
e
n
d
e
n
t
t
h
i
r
d
-
p
a
r
t
y
a
n
a
l
y
s
i
s
(
f
o
r
e
x
a
m
p
l
e
H
P
L
C
o
r
m
a
s
s
s
p
e
c
t
r
o
m
e
t
r
y
w
i
t
h
a
c
e
r
t
i
f
i
c
a
t
e
o
f
a
n
a
l
y
s
i
s
t
i
e
d
t
o
t
h
e
s
p
e
c
i
f
i
c
l
o
t
)
i
s
t
h
e
o
n
l
y
w
a
y
t
o
c
h
a
r
a
c
t
e
r
i
z
e
a
s
a
m
p
l
e
,
a
n
d
e
v
e
n
a
c
l
e
a
n
C
O
A
d
o
e
s
n
o
t
m
a
k
e
h
u
m
a
n
u
s
e
l
a
w
f
u
l
o
r
s
a
f
e
.
T
r
e
a
t
a
l
l
v
e
n
d
o
r
p
u
r
i
t
y
a
n
d
p
o
t
e
n
c
y
c
l
a
i
m
s
a
s
u
n
v
e
r
i
f
i
e
d
m
a
r
k
e
t
i
n
g
.

Safer, legal alternative we recommend

NMN It To Win It. For the same cellular-aging/longevity goal, our NMN (a NAD+ precursor) is a legal supplement covering a similar mechanism.

See our recommended pick

Find SLU-PP-332 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Is SLU-PP-332 proven to work in humans?

No. Every efficacy result to date is from cell-based assays and mouse studies. There are no published human clinical trials, no human efficacy data, and no human safety data. Any claim that it produces exercise-like benefits in people is an extrapolation from animals, not an established fact.

Is it legal to buy?

It is not an FDA-approved drug and not a lawful dietary supplement. It is sold only as a research-use-only chemical labeled not for human consumption. Marketing or using it for human consumption is outside its lawful status, and vendor material is unregulated as to identity, purity, and dose.

What dose is used?

This reference does not provide dosing guidance. There is no established human dose and no human pharmacokinetic data. Published animal doses were given by injection and cannot be scaled to humans. Anyone considering it should consult a qualified clinician rather than rely on vendor figures or forum protocols.

How does it differ from a GLP-1 drug like semaglutide?

They are unrelated. GLP-1 agonists are approved drugs that reduce appetite and food intake through gut-hormone signaling. SLU-PP-332 is an unapproved ERR agonist that, in mice, increased energy expenditure and fat oxidation without changing food intake. Only GLP-1 drugs have human trial data and regulatory approval.

Is it safe?

Unknown in humans. Short rodent studies did not report severe acute toxicity, but there is no long-term, cardiac, hepatic, carcinogenicity, or reproductive safety data in any species relevant to human use, and vendor material carries additional purity and sterility risks. It should be regarded as an experimental compound with an uncharacterized human safety profile.

Why is it called an exercise mimetic?

Because it activates the ERR/PGC-1alpha transcriptional program that normally ramps up during aerobic exercise, driving mitochondrial-biogenesis and fat-oxidation genes. In mice this produced some exercise-like metabolic changes without physical activity. It is a proposed mechanism supported preclinically, not a substitute for exercise validated in humans.

References & further reading

PubMed: SLU-PP-332 estrogen-related receptor agonist metabolic syndrome
PubMed: SLU-PP-332 ERR agonist exercise mimetic mice
PubMed: SLU-PP-915 orally active estrogen-related receptor agonist aerobic exercise capacity
PubMed: estrogen-related receptor alpha PGC-1alpha mitochondrial biogenesis skeletal muscle
ClinicalTrials.gov: SLU-PP-332